Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Shaw, chairperson of Biocon Ltd, urges the Indian government to eliminate taxes on drugs for cancer and chronic diseases.

China's rural healthcare gap impacts timely medical response; the EU plans to ban 'forever chemicals'; North America eases ...